Acarbose is an intestinal α-glucosidase inhibitor effective in significantly reducing carbohydrates absorbtion. Many studies demonstrate a real impact of acarbose monotherapy on the short and long term improvement of glycaemic control, with a pattern similar to that observed with other drugs used in diabetes mellitus as sulphonylureas. Together with sulphonylureas, acarbose improves metabolic control and seems to slow b-cell impairment by reducing post-prandial insulin peaks. In type 1 diabetic patients, acarbose stabilizes and reduces insulin need during the treatment time. Acarbose is well tolerated with small side effects, particularly due to gastroenteric problems. Moreover, acarbose reduces the incidence of hypoglycaemic events also in the olders, both on rest and during sport activity. Consistent evidences which suggest a possible role of acarbose in preventing diabetes mellitus in patients with IGT and in preventing cardiovascular diseases are available. In obese or overweighted patients, acarbose is useful, in association with diet, in reducing and stabilizing body weight. In patients with diabetic neuropathy, acarbose reduces the number of hypotensive episodes.
|Translated title of the contribution||Acarbose features and its use in diabetic patient management|
|Number of pages||12|
|Journal||Trends in Medicine|
|Publication status||Published - Jul 2005|
ASJC Scopus subject areas
- Internal Medicine
- Pharmacology (medical)